An immunologically active chimaeric protein containing herpes simplex virus type 1 glycoprotein D

Area of Science:

• Virology
• Immunology
• Biotechnology

Background:

• Herpes simplex virus types 1 and 2 (HSV-1, HSV-2) cause persistent and latent infections with significant clinical manifestations.
• Current vaccines for HSV-1 and HSV-2 have shown limited success in terms of safety and efficacy.
• Neutralizing antibodies against specific HSV glycoproteins, particularly glycoprotein D (gD), can inhibit viral infectivity.

Purpose of the Study:

• To construct and express a novel chimeric protein incorporating HSV-1 gD for potential therapeutic applications.
• To evaluate the immunogenicity and neutralizing capacity of the chimeric protein against HSV-1 and HSV-2.

Main Methods:

• Construction of a hybrid gene encoding a chimeric protein (gD-beta-gal) comprising HSV-1 gD, bacteriophage lambda Cro, and E. coli beta-galactosidase.
• High-level expression of the chimeric protein in E. coli.
• Immunization of rabbits with the chimeric protein and assessment of elicited antibody responses.

Main Results:

• The chimeric gD-beta-gal protein was successfully expressed at high levels in E. coli.
• Antibodies generated against the chimeric protein could immunoprecipitate gD from HSV-1 and HSV-2 infected cells.
• These antibodies demonstrated in vitro neutralization of both HSV-1 and HSV-2 infectivity.

Conclusions:

• The chimeric gD-beta-gal protein is a viable candidate for eliciting neutralizing antibodies against HSV.
• This approach represents a promising strategy for developing new vaccines or therapeutics against HSV-1 and HSV-2 infections.